Table 1 Clinical features, therapies, and prognosis of 21 rheumatoid arthritis (RA) patients with other iatrogenic immunodeficiency-associated (OIIA) T- and NK-cell lymphoproliferative disorders (LPDs)
No. | Age, onset of LPDs (y) | Sex | RA duration (months) | MTX duration (months) | Other biologic drugs for RA | LDH (U/L) | sIL2R (U/ml) | Clinical stage | Regression of LPDsa | Chemotherapies | Follow-up (months)/ outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 83 | M | 78 | 60 | - | 520 | 1316 | III | − | VP-16, THP-COP | 13/d |
2 | 77 | F | 48 | 48 | - | 208 | 604 | II | − | THP-COP, Rad | 63/d |
3 | 71 | F | 37 | 36 | TNF inhibitor (adalimumab) | 130 | 1480 | III | − | CHOP | 66/a |
4 | 54 | F | 36 | 36 | - | 196 | 559 | IV | − | CHOP | 23/a |
5 | 66 | M | 11 | 11 | - | 167 | 464 | III | + | − | 102/a |
6 | 77 | F | 80 | 70 | - | 296 | 402 | II | + | − | 55/a |
7 | 63 | F | 168 | 168 | - | 162 | 429 | IV | + | − | 70/a |
8 | 47 | M | 48 | 48 | Anti-IL6 receptor Ab (tocilizumab) | 567 | 18029 | IV | − | Brentuximab vedotin | 8/d |
9 | 68 | F | 70 | 70 | - | 272 | nt | II | + | − | 31/a |
10 | 70 | M | 80 | 4 | - | 547 | 8010 | IV | + | − | 58/d |
11 | 73 | F | 12 | 12 | - | 657 | 11165 | III | + | − | 117/a |
12 | 69 | F | 84 | 36 | - | 598 | 58090 | IV | − | THP-COP | 2/d |
13 | 77 | F | 168 | 108 | - | 1590 | 2662 | IV | − | - | 1/d |
14 | 59 | F | 36 | 36 | - | 1915 | 21816 | IV | − | THP-COP | 4/d |
15 | 61 | F | 150 | 57 | - | 503 | 8088 | IV | + | − | 156/a |
16 | 45 | F | 31 | 31 | - | 370 | 817 | IV | + | − | 107/a |
17 | 58 | M | 29 | 29 | - | 521 | 4523 | I | + | − | 3/a |
18 | 59 | F | 52 | 39 | TNF inhibitor (infliximab) | 1794 | nt | IV | − | VP-16, CSA | 102/a |
19 | 81 | F | 25 | 25 | - | 334 | 2291 | III | + | − | 13/a |
20 | 31 | M | 70 | 60 | Anti-CTLA4 Ab (abatacept) | 700 | 2010 | I | + | − | 129/a |
21 | 55 | F | 204 | 120 | - | 216 | 1410 | III | + | − | 157/a |
Total | 64 (median) | M/F: 6/15 | 72 (median) | 53 (median) | na | 584 (median) | 7588 (median) | I/II/III/IV: 2/3/6/10 | 12 | 8 | na |